Biocon receives USFDA approval for Liraglutide injection gSaxenda for weight management
Biocon receives USFDA approval for Liraglutide injection gSaxenda for weight management is drawing significant interest across the industry.
Biocon Ltd has received US FDA approval for its complex formulation Liraglutide Injection 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda). The drug-device combination is indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Biathlon-Samuelsson puts struggles behind him to secure relay bronze for Sweden
- If the Winter Olympics went interplanetary, where else could you ski in the solar system?
- India allows export of 25 lakh tonnes of wheat despite overall ban
- Music Review: A post-‘Brat’ Charli xcx broods on the ‘Wuthering Heights’ soundtrack
Source: Original →